CLADRIBINE (cla'dri-been) Leustatin Classifications: antineoplastic; antimetabolite, purine antagonist Prototype: 6-mercaptopurine Pregnancy Category: D |
1 mg/mL injection
Cladribine is a synthetic antineoplastic agent with selective toxicity toward certain normal and malignant lymphocytes and monocytes. It accumulates intracellularly, preventing repair of single-stranded DNA breaks and ultimately interfering with cellular metabolism and DNA synthesis.
Cladribine is cytotoxic to both actively dividing and quiescent lymphocytes and monocytes, inhibiting both DNA synthesis and repair.
Treatment of hairy cell leukemia.
Advanced cutaneous T-cell lymphomas, chronic lymphocytic leukemia, non-Hodgkin's lymphomas, acute myeloid leukemia, autoimmune hemolytic anemia, mycosis fungoides.
Hypersensitivity to cladribine; pregnancy (category D).
Hepatic or renal impairment. Safety and efficacy in children not established.
Hairy Cell Leukemia Adult: IV 0.09 mg/kg/d by 7 d continuous infusion Chronic Lymphocytic Leukemia Adult: IV 0.1 mg/kg/d by 7 d continuous infusion or 0.0280.14 mg/kg/d as 2 h infusion for 5 consecutive d |
Intravenous PREPARE: IV Infusion (single daily dose): IV infusion (7-day dose): The calculated dose of cladribine is injected into an infusion reservoir using a 0.22 micron filter. An amount of bacteriostatic NS is added through a 0.22 micron filter to bring the total to 100 mL. (Note: reservoir usually prepared by the pharmacist.) ADMINISTER: IV Infusion (single daily dose): Distribute evenly over ordered time (i.e., 2 h or 24 h). IV infusion (7-day dose): Give through a central line and control by a pump device (e.g., Deltec pump) to deliver 100 mL evenly over 7 d. INCOMPATIBILITIES Solution/additive: Do not mix with any other diluents or drugs. |
Assessment & Drug Effects
Patient & Family Education